基于肺组织病理学特征定义的肺炎亚表型
研究对276例老年肺炎参与者的快速尸检肺样本进行20项组织病理学特征评分(如2型细胞增生或坏死),用统计学分析特征间关联并以聚类将参与者分为组织病理相似的组,用多重免疫荧光定量肺白细胞,并检查多种感染小鼠的肺样本以评估可推广性。结果显示肺炎参与者聚类为7种具有不同组织病理学特征的亚表型;所测白细胞(包括巨噬细胞、中性粒细胞、T细胞和B细胞)各与特定组织学特征及肺病理亚表型相关;小鼠模型中观察到对应亚表型,但人肺中部分组织学特征从未在小鼠中观察到。作者认为该框架可能有助于为部分肺炎患者开发和测试宿主导向治疗。
要点
- 276例老年肺炎死者肺组织经20项组织病理特征评分与聚类,分为7种组织病理学特征不同的肺炎亚表型。
- 所测肺白细胞(巨噬细胞、中性粒细胞、T细胞、B细胞)各与特定组织学特征及肺病理亚表型相关。
- 小鼠感染模型中观察到对应亚表型,但人肺中部分组织学特征从未在小鼠中观察到。
- 作者认为该框架可能有助于为部分肺炎患者开发和测试宿主导向治疗。
适用人群与场景
- 276例老年肺炎参与者,肺样本来自快速尸检。
- 小鼠模型:多种不同感染的小鼠肺样本。
研究设计与关键结果
- 研究对276例老年肺炎参与者的快速尸检肺样本评分20项组织病理学特征(如2型细胞增生或坏死),经统计分析与聚类分为7种组织病理学特征不同的亚表型。
- 所测每种白细胞(包括巨噬细胞、中性粒细胞、T细胞和B细胞)均与特定组织学特征及肺病理亚表型相关。
- 小鼠模型中观察到对应亚表型,但人肺中部分组织学特征从未在小鼠中观察到。
证据类型、等级与局限
- 证据类型:基于快速尸检肺样本的组织病理学评分与聚类分析研究,并辅以小鼠模型验证。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,识别肺炎的不同肺病理亚表型为关联判别性生物标志物、明确潜在机制及测试治疗反应提供了新机会。
- 作者认为,该框架可能有助于为部分肺炎患者开发和测试宿主导向治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: Establishing subphenotypes of pneumonia based on host biology will be a step toward using host-directed therapies (to complement microbe-directed therapies) more rationally and precisely. Pneumonia is a pulmonary pathophysiology, but histopathological changes within the lungs have not been leveraged for subphenotyping.
OBJECTIVE: To determine whether pneumonia includes distinct subphenotypes based on pulmonary histopathology.
METHODS: We scored 20 histopathology features (eg, type 2 cell hyperplasia or necrosis) across rapid autopsy lung samples from 276 elderly participants with pneumonia. Statistical analyses were used to define associations among histopathological features, and clustering segregated participants into groups of similar histopathologies. Lung leukocytes were quantified using multispectral immunofluorescence. Lung samples from mice with varied infections were similarly examined to assess generalizability of findings and utility of experimental models.
MEASUREMENTS AND MAIN RESULTS: Participants with pneumonia clustered into 7 subphenotypes with distinct histopathology signatures. Some histopathological features tended to associate with others, and each of the leukocytes measured (including macrophages, neutrophils, T cells, and B cells) associated with select histology features and pulmonary pathology subphenotypes. Corollary subphenotypes were observed in mouse models, although some histology features observed in human lungs were never observed in mice.
CONCLUSIONS: By illuminating a spectrum of histopathologies and discriminating discrete subphenotypes of pneumonia, these studies provide a framework that may prove useful for developing and testing host-directed therapies for subsets of pneumonia patients.At a Glance CommentaryScientific Knowledge on the Subject: Distinguishing subphenotypes of critical illnesses including pneumonia, ARDS, and sepsis is being pursued as a promising step towards optimizing application of host-directed therapies. Pneumonia is a pulmonary pathophysiology, making lung-specific data especially meaningful for establishing subphenotypes. While pneumonia associates with multiple different pathologic features in the lung, whether pneumonia subphenotypes can be distinguished by segregating sets of pulmonary histopathology features has yet to be directly addressed.What This Study Adds to the Field: Using unbiased machine learning to interrogate pathological assessments of lung tissues from people who died with pneumonia, seven different patterns of pulmonary pathology are discriminated. These pathological subphenotypes involve different types of immune cells in the lungs, and they can be partially captured with mouse models of lower -respiratory infection. Recognition of distinct pulmonary pathology subphenotypes of pneumonia suggests new opportunities for associating discriminatory biomarkers, defining underlying mechanisms, and testing responses to therapies.
参考来源
- Shastry A, Hiller BE, Sanders NL, et al. Subphenotypes of pneumonia defined by pulmonary histopathological features. Am J Respir Crit Care Med. 2026. PMID: 42089675. doi:10.1093/ajrccm/aamag182
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。